^
Association details:
| Biomarker: | EGFR C797S + EGFR T790M + EGFR L858R |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | HBI-2376 (PTPN11 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1041 / 15 - HBI-2376, HUYABIO clinical stage SHP2 inhibitor, possess robust in vitro potency and in vivo efficacy in several preclinical tumor models carrying KrasG12C or EGFR mutations
Published date:
03/09/2022
Excerpt:
...in vitro studies showed greater potency of HBI‑2376 to inhibit cell proliferation in a variety of cancer cell lines...HBI-2376 found to be more efficacious in tumor growth inhibition than TNO-155 and RMC-4550 in NCI-H1975 L858R_T790M_C797S osimertinib-resistant cell line and other tumor models.
